Innovative Nanomedicine Delivery: Targeting Tumor Microenvironment to Defeat Drug Resistance
Pharmaceutics · 03.12.2024 · 16 (12) · 1549
DOI: 10.3390/pharmaceutics16121549 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 03.12.2024. Verfasst von Wenjun Meng und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China. Die Arbeit wurde bisher 66-mal zitiert (Crossref) und nennt 179 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Technology Innovation Research and Development Project of Chengdu Science and Technology Bureau, CAMS Innovation Fund for Medical Sciences (CIFMS), National Key R&D·Program of China.
Abstract (Originalsprache)
Nanodrug delivery systems have revolutionized tumor therapy like never before. By overcoming the complexity of the tumor microenvironment (TME) and bypassing drug resistance mechanisms, nanotechnology has shown great potential to improve drug efficacy and reduce toxic side effects. This review examines the impact of the TME on drug resistance and recent advances in nanomedicine delivery systems to overcome this challenge. Characteristics of the TME such as hypoxia, acidity, and high interstitial pressure significantly reduce the effectiveness of chemotherapy and radiotherapy, leading to increased drug resistance in tumor cells. Then, this review summarizes innovative nanocarrier designs for these microenvironmental features, including hypoxia-sensitive nanoparticles, pH-responsive carriers, and multifunctional nanosystems that enable targeted drug release and improved drug penetration and accumulation in tumors. By combining nanotechnology with therapeutic strategies, this review offers a novel perspective by focusing on the innovative design of nanocarriers that interact with the TME, a dimension often overlooked in similar reviews. We highlight the dual role of these nanocarriers in therapeutic delivery and TME modulation, emphasize their potential to overcome drug resistance, and look at future research directions.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China.
- Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China.
- Division of Abdominal Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China.
ORCID-Profile: Wenjun Meng
Förderung
- Technology Innovation Research and Development Project of Chengdu Science and Technology Bureau
- CAMS Innovation Fund for Medical Sciences (CIFMS)
- National Key R&D·Program of China
- National Key R&D Program of China
Zitieren
APA
Meng, W., Huang, L., Guo, J., Xin, Q., Liu, J., & Hu, Y. (2024). Innovative Nanomedicine Delivery: Targeting Tumor Microenvironment to Defeat Drug Resistance. Pharmaceutics, 16(12), 1549. https://doi.org/10.3390/pharmaceutics16121549
Vancouver
Meng W, Huang L, Guo J, Xin Q, Liu J, Hu Y. Innovative Nanomedicine Delivery: Targeting Tumor Microenvironment to Defeat Drug Resistance. Pharmaceutics. 2024;16(12):1549. doi:10.3390/pharmaceutics16121549
BibTeX
@article{Meng2024,
author = {Meng, Wenjun and Huang, Li and Guo, Jiamin and Xin, Qing and Liu, Jiyan and Hu, Yuzhu},
title = {Innovative Nanomedicine Delivery: Targeting Tumor Microenvironment to Defeat Drug Resistance},
journal = {Pharmaceutics},
year = {2024},
volume = {16},
number = {12},
pages = {1549},
doi = {10.3390/pharmaceutics16121549}
}
EUVIMED